A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces...

Area of Science:

• Molecular Biology
• Cancer Research
• Antisense Technology

Background:

• Bcl-2 and Bcl-xL are anti-apoptotic proteins frequently overexpressed in solid tumors, contributing to cancer cell survival.
• Targeting these proteins offers a potential therapeutic strategy for various malignancies.
• A conserved homologous region in bcl-2 and bcl-xL mRNA presents an opportunity for simultaneous targeting.

Purpose of the Study:

• To investigate the potential of novel antisense oligonucleotides to simultaneously down-regulate bcl-2 and bcl-xL expression.
• To assess the ability of these oligonucleotides to induce apoptosis in lung cancer cell lines.
• To identify a potent bispecific antisense oligonucleotide for therapeutic development.

Main Methods:

• Design and synthesis of three modified phosphorothioate oligonucleotides targeting the homologous region of bcl-2 and bcl-xL mRNAs.
• Assessment of oligonucleotide effects on bcl-2 and bcl-xL mRNA and protein levels in small cell and non-small cell lung cancer cell lines.
• Evaluation of apoptosis induction using propidium iodide uptake, caspase-3-like protease activity assays, and nuclear morphology analysis.

Main Results:

• All tested oligonucleotides successfully down-regulated bcl-2 and bcl-xL expression.
• Oligonucleotide 4625 demonstrated the strongest bispecific activity, with no mismatches to bcl-2 and three mismatches to bcl-xL.
• This bispecific activity led to significant induction of apoptotic cell death across all tested lung cancer cell lines.

Conclusions:

• A novel bcl-2/bcl-xL bispecific antisense oligonucleotide (4625) has been identified.
• This compound effectively induces apoptosis in lung cancer cells by down-regulating both target proteins.
• This bispecific antisense oligonucleotide represents a promising therapeutic candidate for cancers overexpressing Bcl-2 and/or Bcl-xL.